Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw an uptick in trading volume on Thursday. Approximately 603,075 shares were traded during mid-day trading, an increase of 152% from the previous session’s volume of 238,886 shares. The stock last traded at $19.51 and had previously closed at $19.57.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Chugai Pharmaceutical currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

The stock’s 50 day simple moving average is $21.41 and its 200-day simple moving average is $23.78. The firm has a market cap of $64.12 billion, a price-to-earnings ratio of 21.17 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Friday, July 24th. The company reported $0.22 EPS for the quarter. The business had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. On average, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.